We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+9.39%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.45B
AUM Growth
-$251M
Cap. Flow
+$217M
Cap. Flow %
8.85%
Top 10 Hldgs %
50.47%
Holding
123
New
19
Increased
24
Reduced
18
Closed
19

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$65.2M
2
GOSS icon
Gossamer Bio
GOSS
+$34.6M
3
XLRN
Acceleron Pharma
XLRN
+$26.3M
4
EPZM
Epizyme, Inc
EPZM
+$19.6M
5
BPMC
Blueprint Medicines
BPMC
+$18.5M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$10.4M
2
BLUE
bluebird bio
BLUE
+$10.2M
3
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$10M
4
ANAB icon
AnaptysBio
ANAB
+$9.57M
5
ARGX icon
argenx
ARGX
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 65.35%
2 Consumer Discretionary 16.48%
3 Miscellaneous 14.54%
4 Technology 3.08%
5 Real Estate 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
101
Ironwood Pharmaceuticals
IRWD
$681M
$1.25M 0.05%
131,975
– –
CMRX
102
DELISTED
Chimerix, Inc.
CMRX
$1.05M 0.04%
500,000
-500,000
-50% -$1.14M
NVLN
103
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$315K 0.01%
256,400
– –
TRIL
104
DELISTED
Trillium Therapeutics Inc.
TRIL
$99K ﹤0.01%
150,000
– –
ALNY icon
105
CALL
Alnylam Pharmaceuticals
ALNY
$32.2B
– –
-300,000
Closed -$21.9M
ANAB icon
106
AnaptysBio
ANAB
$1.62B
– –
-150,000
Closed -$9.57M
BLUE
107
CALL
DELISTED
bluebird bio
BLUE
– –
-7,720
Closed -$9.92M
BMRN icon
108
CALL
BioMarin Pharmaceuticals
BMRN
$12.4B
– –
-200,000
Closed -$17M
FCX icon
109
CALL
Freeport-McMoran
FCX
$98.9B
– –
-2,000,000
Closed -$20.6M
KYNB
110
CALL
Kyntra Bio
KYNB
$31.9M
– –
-6,000
Closed -$6.94M
MS icon
111
CALL
Morgan Stanley
MS
$317B
– –
-1,500,000
Closed -$59.5M
MU icon
112
CALL
Micron Technology
MU
$1.05T
– –
-400,000
Closed -$12.7M
VALE icon
113
CALL
Vale
VALE
$62B
– –
-500,000
Closed -$6.59M
WFC icon
114
CALL
Wells Fargo
WFC
$269B
– –
-1,500,000
Closed -$69.1M
WYNN icon
115
CALL
Wynn Resorts
WYNN
$9.04B
– –
-100,000
Closed -$9.89M
YMAB
116
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-50,000
Closed -$1.02M
QTTB icon
117
Q32 Bio
QTTB
$319M
– –
-5,556
Closed -$2.24M
ONC
118
CALL
BeOne Medicines Ltd
ONC
$39.3B
– –
-200,000
Closed -$28.1M
MRNS
119
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-125,000
Closed -$1.44M
CLVS
120
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-200,000
Closed -$3.59M
MNTA
121
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-200,000
Closed -$2.21M
MDCO
122
CALL
DELISTED
Medicines Co
MDCO
– –
-600,000
Closed -$11.5M
CMTA
123
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
– –
-850,000
Closed -$10M
1 2 3 4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2019 Portfolio in Review

As of Q1 2019, Artal Group held 123 positions worth $2.45B, down 9.3% from $2.7B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Artal Group deployed $217M of net new capital in Q1 2019, opening 19 new positions and adding to 24 existing holdings. Its largest new stake was NVIDIA: 16,800,000 shares worth $75.4M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 49% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $10.4M trimmed.

  • Artal Group's largest Q1 2019 buy was NVIDIA: 16,800,000 shares worth $75.4M.
  • Artal Group added most to Acceleron Pharma in Q1 2019, an estimated $26.3M increase.
  • Artal Group's biggest Q1 2019 reduction was Array Biopharma Inc, cutting an estimated $10.4M.
  • Artal Group fully exited Clementia Pharmaceuticals Inc. in Q1 2019, selling an estimated $10M.
  • Artal Group's ten largest holdings make up 50% of its $2.45B portfolio in Q1 2019.
  • Artal Group opened 19 new positions and closed 19 in Q1 2019.
  • Artal Group's portfolio value fell 9.3% quarter-over-quarter to $2.45B.

Based on Artal Group's 13F filing for Q1 2019, filed 10 May 2019.